Volpara has entered into a Scheme Implementation Agreement with Lunit, Inc. under which Lunit would acquire all of Volpara’s shares at a price of A$1.15 per share in cash.  

Working together, Lunit and Volpara would have the opportunity to develop products that very few companies are in a position to do. This is expected to put us at the forefront of cancer technology and position us as a global leader in our field. 

Lunit and Volpara are unified in our belief in the power of AI-enabled software and together, our two organisations have the potential to create a powerful engine to better diagnose and care for cancer worldwide. Volpara’s established presence in the US and Lunit’s complementary global footprint and AI expertise would create a compelling portfolio of advanced AI enabled solutions for radiology and other healthcare specialties.

The purchase is expected to close Q2 2024.

                    Corporate enquiries                                     Investor relations

                    Teri Thomas, CEO & MD                                Shareholder Information Line
                    Volpara Health Technologies                       Toll: 1300 513 794
                    teri.thomas@volparahealth.com                AU Toll-free: +61 2 9066 4082
                    t: +64 4 499 6029                                           NZ Toll-free: +64 9 889 6570

                    Media enquiries                                               Customer Contacts

                    Clive Mathieson                                               info@volparahealth.com
                    Cato & Clive                                                      UNITED STATES +1 800 305 3865
                    clive@catoandclive.com                                EUROPE +44 203 051 1029
                    t: +61 411 888 425                                             AUSTRALIA +61 1800 370 623
                    NEW ZEALAND +64 0800 444 148